Atley Solutions and Perceptive Discovery Form Strategic Partnership to Advance Astatine-211 Radiopharmaceutical Development
核心洞察
Atley Solutions (搜索) has sold two C100 automated manufacturing modules to Perceptive Discovery (搜索), marking the first installations at commercial CRO facilities in the US and UK.
The partnership establishes pioneering astatine-211 (搜索) capabilities across both regions, providing standardized and scalable manufacturing infrastructure for targeted alpha therapy (搜索) development.
This collaboration aims to accelerate discovery and development of next-generation radiopharmaceutical candidates based on astatine-211 (搜索), one of the most promising radionuclides for precision oncology (搜索).
Atley Solutions (搜索) and Perceptive Discovery (搜索) announced a strategic collaboration centered on the sale of two Atley C100 modules, establishing the first commercial contract research organization (CRO) capabilities for astatine-211 (搜索) (At-211) radiopharmaceutical development in both the United States and United Kingdom. The partnership represents a significant milestone in expanding global access to targeted alpha therapy (搜索) development infrastructure.
First Commercial CRO Installations Mark Industry Milestone
One Atley C100 module will be installed at Perceptive Discovery (搜索)'s laboratory in Needham, Massachusetts, marking the first-ever installation of the technology at a commercial CRO in the United States. The second unit will be deployed at Perceptive Discovery's partner laboratory at Queen Mary University of London, representing the first installation of the Atley C100 in the United Kingdom.
The Atley C100 is described as the world's first and only automated manufacturing module purpose-built for At-211 radiopharmaceuticals (搜索). The system delivers standardized, reproducible, and scalable manufacturing with a high degree of operator protection, addressing key challenges in radionuclide production and supply chain scalability.
Expanding Infrastructure for Targeted Alpha Therapy
The installations will enable standardized, reproducible manufacturing of At-211 radiopharmaceuticals (搜索) and provide a strong foundation for discovery, preclinical evaluation, and translational development. The systems offer scalable platforms suited for early research through to clinical manufacturing, establishing the first commercial CRO environments with dedicated At-211 capabilities in both the UK and US.
"At-211 is one of the most promising radionuclides for targeted radionuclide therapy, and Atley is at the forefront of At-211 innovation," said Ben Murphy, CEO of Perceptive Discovery (搜索). "Through our partnership, the combination of Atley's technology and our world-leading capabilities will accelerate the development of the next generation of radiopharmaceutical products."
Multi-Phase Partnership Strategy
Atley and Perceptive intend to build a multi-phase partnership spanning equipment, services, and knowledge exchange. The shared goal is to enable the broader radiopharmaceutical sector to rapidly explore, validate, and advance new targeted alpha therapy (搜索) candidates based on At-211, which is positioned as one of the most promising radionuclides for next-generation precision oncology (搜索).
Milton Lönnroth, CEO of Atley Solutions (搜索), emphasized the collaboration's significance: "This partnership with Perceptive Discovery (搜索) represents a major step forward for the global At-211 ecosystem. Perceptive Discovery is a global leader in radiopharmaceutical CRO services, and by equipping them with the Atley C100, we are enabling our joint customers to develop At-211-based radiopharmaceuticals (搜索) faster and more efficiently. This marks the beginning of a long-term collaboration that will shape the field for years to come."
Supporting Global Radiopharmaceutical Development
The partnership is expected to play a significant role in establishing robust At-211 infrastructure globally and in supporting biotech and pharmaceutical companies seeking access to specialized capabilities. With two systems deployed across the US and UK, Perceptive Discovery (搜索) will establish pioneering At-211 capabilities in both regions, providing clients and collaborators with direct access to cutting-edge infrastructure.
Perceptive Discovery (搜索) delivers advanced preclinical and translational solutions with deep expertise in radiochemistry, in-vivo imaging, oncology and CNS models, dosimetry, assay development, and radioligand therapy. The company provides integrated workflows that generate high-quality, decision-ready data for biotech and pharmaceutical partners worldwide.